TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Bluefish Pharmaceuticals AB (publ)
Closing information (x1000 NOK)
Closing information | 2024/04 (consolidated) | 2023/04 (consolidated) | 2021/12 (consolidated) |
Turnover |
487,335
|
559,907
|
375,948 |
Financial expenses |
29,618
|
42,663
|
15,016 |
Earnings before taxes |
32,748
|
-93,477
|
-18,504 |
EBITDA |
47,820
|
-28,553
|
17,168 |
Total assets |
592,009
|
560,551
|
554,071 |
Current assets |
465,572
|
426,519
|
446,540 |
Current liabilities |
305,210
|
210,021
|
445,679 |
Equity capital |
45,233
|
-43,177
|
86,499 |
- share capital |
21,698
|
22,376
|
21,049 |
Employees (average) |
126
|
128
|
124 |
Financial ratios
Fiscal year | 2024/04 (consolidated) | 2023/04 (consolidated) | 2021/12 (consolidated) |
Solvency |
7.6%
|
-7.7%
|
15.6% |
Turnover per employee |
3,868
|
4,374
|
3,032 |
Profit as a percentage of turnover |
6.7%
|
-16.7%
|
-4.9% |
Return on assets (ROA) |
10.5%
|
-9.1%
|
-0.6% |
Current ratio |
152.5%
|
203.1%
|
100.2% |
Return on equity (ROE) |
72.4%
|
216.5%
|
-21.4% |
Change turnover |
-55,611
|
160,267
|
-28,201 |
Change turnover % |
-10%
|
40%
|
-7% |
Chg. No. of employees |
-2
|
4
|
-5 |
Chg. No. of employees % |
-2%
|
3%
|
-4% |
Total value of public sale
Fiscal year | 2024/04 (consolidated) | 2023/04 (consolidated) | 2021/12 (consolidated) |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.